drugset
drugset / Trial / NCT05026008

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SR1375

NCT05026008 ↗

Phase 1 Completed 72 enrolled Shanghai SIMR Biotechnology Co., Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, 2-part study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of SR1375 in healthy volunteers

Timeline

Start
2021-09-30
Primary completion
2022-11-30
Completion
2023-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SR1375 Unknown 1 mg Oral
Subject SR1375 Unknown 3 mg Oral
Subject SR1375 Unknown 5 mg Oral
Subject SR1375 Unknown 10 mg Oral
Subject SR1375 Unknown 15 mg Oral
Subject SR1375 Unknown 30 mg Oral
Subject SR1375 Unknown 50 mg Oral
Subject SR1375 Unknown 100 mg Oral
Subject SR1375 Unknown 200 mg Oral

Indications

No indication recorded.